SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCJuly 15, 2026

Proton pump inhibitors and antibiotics linked to reduced durvalumab benefit in unresectable stage III NSCLC

A new analysis of the phase 3 PACIFIC trial has found that patients with unresectable stage III non-small-cell lung cancer (NSCLC) who were taking proton pump inhibitors or antibiotics at baseline derived markedly less benefit from durvalumab after chemoradiotherapy than patients who were not. The pattern, published in The Lancet Oncology, was absent in the trial's placebo group, pointing to an interaction with the drug rather than a general marker of sicker patients.
Share

In brief

  • In a post-hoc analysis of the phase 3 PACIFIC trial, patients with unresectable stage III NSCLC taking proton pump inhibitors at baseline had shorter progression-free survival (9.4 vs 17.2 months) and overall survival (33.0 vs 57.9 months) on durvalumab than patients who were not.
  • Baseline antibiotic use was likewise associated with shorter progression-free survival (9.2 vs 15.6 months), although the difference in overall survival did not reach statistical significance.
  • No such associations appeared in the placebo group, pointing to an interaction with durvalumab rather than a general marker of sicker patients.
  • The analysis is observational and cannot show that the medications caused the poorer outcomes; the authors call for prospective studies with standardised exposure definitions and integrated microbiome profiling.

Read the full paper in The Lancet Oncology →

Already linked to weaker immunotherapy response in advanced disease

Durvalumab, a PD-L1 immune checkpoint inhibitor, is given as consolidation treatment after concurrent chemoradiotherapy in unresectable stage III NSCLC, the approach established by the original PACIFIC trial. Earlier work in advanced and metastatic cancers had linked two commonly prescribed classes of medication, proton pump inhibitors and systemic antibiotics, to weaker responses to checkpoint inhibitors, an effect attributed to disruption of the gut microbiome. Whether the same held in earlier-stage disease treated with curative intent had not been established. The investigators examined the question using the completed PACIFIC dataset at its final five-year cutoff.

Study at a glance

  • Source trial: PACIFIC (NCT02125461), phase 3, randomised, double-blind, placebo-controlled; this is a post-hoc analysis at the final 5-year data cutoff
  • Population: 660 of 713 randomised patients with unresectable stage III NSCLC (449 durvalumab, 211 placebo)
  • Exposures examined: baseline proton pump inhibitors (263 patients, 40%) and systemic antibiotics (69 patients, 10%)
  • Endpoints: progression-free survival and overall survival, compared by exposure
  • Median follow-up: 62.4 months

Worse survival on durvalumab, absent on placebo

Among patients treated with durvalumab, baseline proton pump inhibitor use was associated with shorter progression-free survival, a median of 9.4 months versus 17.2 months without exposure (hazard ratio 1.57; 95% CI 1.28–1.93; p<0.0001), and shorter overall survival, 33.0 months versus 57.9 months (hazard ratio 1.66; 95% CI 1.30–2.13; p<0.0001). Baseline antibiotic use was likewise associated with shorter progression-free survival, 9.2 months versus 15.6 months (hazard ratio 1.50; 95% CI 1.08–2.10; p=0.016), although the difference in overall survival did not reach statistical significance (hazard ratio 1.33; 95% CI 0.90–1.97; p=0.16).

No such associations appeared in the placebo group, where neither medication class was linked to progression-free or overall survival. The interaction between treatment and proton pump inhibitor exposure was statistically significant for both progression-free survival (p=0.023) and overall survival (p<0.0001); the interaction with antibiotics was not. The authors note that the analysis is observational and cannot show that the medications caused the poorer outcomes.

A possible interaction with the drug, not just sicker patients

Because the association was present with durvalumab but not with placebo, the investigators described the medications as potentially attenuating the drug’s benefit rather than simply marking patients with worse prognosis. They set the finding against the curative intent of treatment at this stage of disease:

“Given the curative intent of treatment in this setting, these results underscore the importance of careful evaluation of concomitant medications when clinically appropriate.”Brunetti et al., The Lancet Oncology (2026)

The authors call for prospective studies with standardised exposure definitions and integrated microbiome profiling to test whether the association is causal and to inform antibiotic stewardship in this setting.

Sources

  1. The Lancet Oncology. Proton pump inhibitors and antibiotics linked to reduced durvalumab benefit in unresectable stage III NSCLC (2026-07-03). thelancet.com

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Alessio Cortellini, David Planchard, Jarushka Naidoo, Jordi Remon and Biagio Ricciuti.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters
SCLC by Solange Peters, Giannis Mountzios, Jacob Sands
Jun 17 2025
VIRTUAL ROUNDTABLE
SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

G. MountziosJ. SandsS. Peters
Girard ADCs
Oct 05 2024
INDUSTRY SYMPOSIUM
Advanced NSCLCADCs

Best Practices in Managing Adverse Events with ADCs in NSCLC

} 18 min

N. Girard
Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min

Sandip Patel & Giannis Mountzios
Oct 04 2024
ILCS 2024
Advanced NSCLC

DEBATE: Balancing Efficacy, Toxicity, and Patient-Centered Care For IO Duration in NSCLC

} 33 min

G. MountziosS. Patel
Jordi Remon
Oct 04 2024
ILCS 2024
Immunotherapies

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

} 25 min

J. Remon
Nov132026
ILCS 2026

The International Lung Cancer Summit 2026

Learn more about the event

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans
Oct252026
ESMO 2026 SYMPOSIUM
SCLC

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

Learn more about the event

M. ReckS. PetersG. MountziosN. Reguart
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
ADCs

The ADC Revolution in Lung Cancer: New Targets, New Opportunities

} 27 min

N. Reguart
Articles
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Oct 03 2026
RESEARCH
Advanced NSCLCTargeted Therapies

KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials

V. Noronha
Oct 02 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

X. Le
Oct 02 2026
RESEARCH
Advanced NSCLCBiomarkersImmunotherapies

High tumour mutational burden was associated with more frequent and earlier immune-related adverse events in advanced NSCLC

B. Ricciuti
Oct 01 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

H. Horinouchi
Sep 30 2026
RESEARCH
Advanced NSCLCSCLCADCs

Pulmonary adverse events affected almost a third of lung cancer patients treated with ADCs in a 24-study meta-analysis

C. Rolfo
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair
Sep 26 2026
RESEARCH
Advanced NSCLCImmunotherapies

Incidental thymic radiation dose was independently associated with metastasis and death in 1107 patients with NSCLC

B. Ricciuti
Portrait of Dr. Alexander Drilon
Sep 23 2026
CONGRESS
Advanced NSCLCTargeted Therapies

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Sep 18 2026
INDUSTRY NEWS
Advanced NSCLCTargeted Therapies

Sevabertinib approved in the US for untreated HER2-mutant NSCLC

Sep 17 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Grade 3 adverse events on the FLAURA2 combination fell from 43% during induction to 14% on osimertinib alone

D. Planchard
Sep 16 2026
CONGRESS
Advanced NSCLCADCs

First-line trastuzumab deruxtecan extended median PFS to 14.3 months in HER2-mutant NSCLC

Sep 15 2026
CONGRESS
Advanced NSCLCImmunotherapies

HARMONi-2: ivonescimab extends overall survival over pembrolizumab in China

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 14 2026
CONGRESS
Advanced NSCLCTargeted Therapies

ARROS-1: first-line zidesamtinib responds in over 90% of ROS1-positive NSCLC

Sep 14 2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 14 2026
CONGRESS
Advanced NSCLCADCs

DESTINY-Lung04: first-line T-DXd adds six months of PFS, no interim survival gain

Sep 14 2026
CONGRESS
Advanced NSCLCTargeted Therapies

PAPILLON final OS: 34.3 vs 27.9 months, HR 0.87 not significant after 76% crossover

Sep 14 2026
CONGRESS
Advanced NSCLCTargeted Therapies

REZILIENT 3: zipalertinib plus chemotherapy adds six months of first-line PFS

Sep 13 2026
CONGRESS
Advanced NSCLCSCLCADCs

WCLC 2026, day 2: MRI surveillance without prophylactic cranial irradiation, and two relapse trials at 13.3 and 18.5 months